# Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

> **NCT01940172** · PHASE1 · COMPLETED · sponsor: **TetraLogic Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Relapsed Epithelial Ovarian Cancer
- Relapsed Primary Peritoneal Cancer
- Relapsed Fallopian Tube Cancer

## Interventions

- **DRUG:** Birinapant
- **DRUG:** Conatumumab

## Key facts

- **NCT ID:** NCT01940172
- **Lead sponsor:** TetraLogic Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2016-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01940172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01940172, "Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT01940172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*